相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
尚未招募
1
50.0%
招募中
1
50.0%
暂无批准数据
- Gain Therapeutics will present Phase 1 results for GT-02287, their brain-penetrant small molecule drug candidate for Parkinson's disease, at the Michael J. Fox Foundation's 16th Annual Conference. - GT-02287 demonstrated favorable safety, target engagement, and therapeutic exposure in healthy volunteers, showing promise as a potential disease-modifying treatment for both GBA1-mutation and idiopathic Parkinson's disease. - The presentation will take place during the "Progress in the Therapeutics Pipeline" session on October 17, 2024, in New York City, highlighting recent preclinical and clinical developments.
- Gain Therapeutics has initiated a Phase 1b clinical trial in Australia for GT-02287, targeting both idiopathic and GBA1-linked Parkinson's disease. - The trial aims to evaluate the safety, tolerability, and biomarker changes over three months of GT-02287 administration in Parkinson's patients. - GT-02287 previously demonstrated a favorable safety profile and significant GCase enzyme engagement in a Phase 1 study with healthy volunteers. - Interim results from the Phase 1b trial are expected by mid-2025, potentially paving the way for Phase 2 trials in the U.S. and EU.
- Gain Therapeutics announced positive topline results from its Phase 1 clinical trial of GT-02287, a novel small molecule therapy targeting GCase for Parkinson's disease. - The study demonstrated that GT-02287 was safe and generally well-tolerated in healthy volunteers, with evidence of central nervous system (CNS) exposure and target engagement. - A Phase 1b trial in Parkinson's disease patients is planned for Q4 2024, with data expected by mid-2025 to assess safety, tolerability, and proof of mechanism. - GT-02287 is an orally administered, brain-penetrant molecule designed to restore GCase function, reduce α-synuclein aggregation, and improve motor and cognitive functions.
